Date: Tuesday, May 5, 2015
Session Time: 5:30pm-6:30pm
Presentation Time: 5:30pm-6:30pm
Location: Exhibit Hall E
The plasma cell dyscrasias (PCD) include a number of entities such as multiple myeloma (MM), primary amyloidosis (AL) and Monoclonal immunoglobulin deposition disease (MIDD). Hematopoietic cell transplantation (HCT) is the only cure for a variety of hematologic and oncologic diseases. Clinically significant renal impairment is a common feature in plasma cell myeloma, affecting 20-55% of patients at initial diagnosis. This circumstance is associated with a high early mortality. The needing for immunosuppression (IS) after HCT will difficult its management, and may precipitate the development of complications. In some patients an effective alternative could be kidney transplantation (KT), however the presence of two transplants will require optimal adjustment .
MATERIAL AND METHODS
From 2003-2010, in our center 540 cadaveric renal transplants were performed, where three patients were carriers of autologous HCT.
We would like to describe our experience with three patients who had a PCD and where initially receiving HCT and subsequently KT.
|Time on HD||62 months||27 months||24 months|
|HLA compatibility||A3||DR14||A2- B15- DR5|
|Maintenance treatment||PDN+ FK||PDN+ FK||PDN+ FK|
|MAU mg/dL||350 mg/dL||169 mg/dL||19,8 mg/dL|
|Recent serum Cr||0.85 mg/dL||1.6 mg/dL||1.4 mg/dL|
|Underlying disease treatment||Lenalidomide||–||Lenalidomide|
|Complications||"Infections/ Cytopenias Plasmacytoma"||Infections / CNI toxicity||Infections / Cytopenias|
In our experience the progress and outcome of KT after HCT were optimal. We would like to address that a higher incidence of cytopenia associated with the combination of IS and other drugs should be detected together with an increase risk of opportunistic infections and the PCD relapse.
To cite this abstract in AMA style:Domínguez-Pimentel V, Fortich-Barrios F, Siverio-Morales O, Martín-Izquierdo E, Jarque-López A, Castillo-Rodríguez NDel, García J, Ríos P, Macía M. Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/kidney-transplantation-after-hematopoietic-cell-transplantation-in-plasma-cell-dyscrasias/. Accessed March 8, 2021.
« Back to 2015 American Transplant Congress